SIRT4-V1: A Novel NAD+-dependent Enzyme with Applications in Drug Screening and Disease Diagnosis

Target Name: SIRT4

NCBI ID: G23409

SIRT4

SIRT4-V1: A Novel NAD+-dependent Enzyme with Applications in Drug Screening and Disease Diagnosis

SIRT4 (Sirtuin 4) is a protein that is expressed in most tissues of the body and plays an important role in various cellular processes. It is a NAD+-dependent enzyme that can convert NAD+ into NADH and is an important component in the intracellular respiratory chain. key players. The variant of SIRT4, SIRT4 variant 1 (SIRT4-V1), has attracted the attention of researchers because of its uniqueness.

SIRT4-V1 has different expression patterns and functions within cells. Through high-throughput sequencing technology and bioinformatics analysis, the researchers found that the expression levels of SIRT4-V1 in liver, kidney, heart and brain tissues were different compared with control tissues. In addition, the expression level of SIRT4-V1 is also related to factors such as age, gender, and health status. These results indicate that SIRT4-V1 has different expression patterns in different tissues and physiological conditions, which provides a broad space for its research as a drug target or biomarker.

Application of SIRT4-V1 in drug screening. SIRT4 is a promising target for the treatment of many diseases because it is overexpressed in many diseases, including neurodegenerative diseases, cardiovascular diseases, and liver diseases. SIRT4-V1, as a new SIRT4 variant, may be a potential drug target. By using high-throughput screening technology, the expression level of SIRT4-V1 can be detected and compounds with SIRT4-V1 expression levels can be screened out. These compounds can be further screened to identify drug molecules with the highest biological activity.

Application of SIRT4-V1 in disease diagnosis. The expression level of SIRT4-V1 can be used as an indicator to evaluate organ function and disease status. For example, decreased SIRT4-V1 expression levels may indicate liver damage, while increased SIRT4-V1 expression levels may indicate kidney disease. By detecting the expression level of SIRT4-V1, it is possible to determine whether a patient has a specific disease and provide important information for the diagnosis and treatment of the disease.

Biological functions of SIRT4-V1. SIRT4 is an important enzyme involved in many important metabolic processes in cells. SIRT4 can convert NAD+ into NADH, a key player in the intracellular respiratory chain. In cells, SIRT4 is also involved in processes such as redox reactions and fatty acid metabolism. In addition, SIRT4 is also involved in many processes of the cell cycle, including mitosis and meiosis. These biological functions make SIRT4 a

Protein Name: Sirtuin 4

Functions: Acts as NAD-dependent protein lipoamidase, biotinylase, deacetylase and ADP-ribosyl transferase (PubMed:16959573, PubMed:17715127, PubMed:24052263, PubMed:25525879). Catalyzes more efficiently removal of lipoyl- and biotinyl- than acetyl-lysine modifications (PubMed:24052263, PubMed:25525879). Inhibits the pyruvate dehydrogenase complex (PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner (PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity (PubMed:16959573, PubMed:17715127). Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest (PubMed:16959573, PubMed:17715127). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation (PubMed:23663782). Acts as a tumor suppressor (PubMed:23562301, PubMed:23663782). Also acts as a NAD-dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis (By similarity). Does not seem to deacetylate PC (PubMed:23438705). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation (PubMed:24043310). Impairs SIRT1-PPARA interaction probably through the regulation of NAD(+) levels (PubMed:24043310). Down-regulates insulin secretion (PubMed:17715127)

The "SIRT4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIRT4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets